Cell Therapeutics, Inc. (NASDAQ: CTIC) is focused on leading the biopharmaceutical industry with their diversified portfolio of proprietary oncology drugs. They manage each and every aspect of the manufacturing process, but outsource their clinical and commercial active pharmaceutical ingredient (API) and finished product (FP) production activities to superior contract manufacturing organizations, both in the US and in Europe. For further information, visit the Company’s web site at www.ctiseattle.com.
- 16 years ago
QualityStocks
Cell Therapeutics, Inc. (NASDAQ: CTIC)
Tags Rodman & Renshaw
Related Post
-
D-Wave Quantum Inc. (NYSE: QBTS) Expands Quantum Optimization Offerings to Accelerate Commercial Adoption
At its Qubits 2025 user conference, D-Wave introduced new hybrid solver capabilities supporting continuous variables…
-
Soligenix Inc. (NASDAQ: SNGX) Advances CiVax Amid Ongoing COVID-19 Threat
An increase in deaths from COVID-19 underscores the persistent danger of the virus and the…
-
Thumzup Media Corp. (NASDAQ: TZUP) Continues Building Its Client Base with Its Proprietary Tech for Ad Campaigns
Social media commerce is expected to grow to $821 billion in 2025[1], demonstrating its importance…